yes… we identified a bigger market worth going after, and so we did.
Would you prefer your companies to continue to raise endless capital, dilute holders to oblivion, in the hopes of commercialising assets with poor data? And then when they realise they’re dogs just quietly erase them from the slide deck and raise more capital to purchase another?
I’m sorry but I know which one I would prefer.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-143
-
- There are more pages in this discussion • 249 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
